Kristen Hege
Direttore/Membro del Consiglio presso MERSANA THERAPEUTICS, INC.
Patrimonio netto: 41 231 $ in data 30/04/2024
Profilo
Kristen M.
Hege is currently an Independent Director at Mersana Therapeutics, Inc., an Independent Non-Executive Director at Adaptimmune Therapeutics Plc, and a Professor at The University of California, San Francisco.
She previously served as the Director at the International Society for Biological Therapy of Cancer from 2016 to 2019, the Director at Baybio Institute from 2014 to 2016, and the Director at the California Life Sciences Association from 2014 to 2016.
She also held positions as the Vice President-Translational Development at Celgene Corp.
from 2010 to 2019, the Vice President-Clinical Research & Development at Cell Genesys, Inc. from 1996 to 2008, and the Chief Medical Officer at Cellerant Therapeutics, Inc. from 2009 to 2010.
Dr. Hege received her undergraduate degree from Dartmouth College in 1984 and her doctorate degree from The University of California, San Francisco in 1989.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
| 15/04/2024 | 14 467 ( 0.01% ) | 41 231 $ | 30/04/2024 | |
-.--% | 01/02/2024 | 0 ( -.--% ) | - $ | 30/04/2024 |
Posizioni attive di Kristen Hege
| Società | Posizione | Inizio |
|---|---|---|
| MERSANA THERAPEUTICS, INC. | Direttore/Membro del Consiglio | 01/08/2016 |
| ADAPTIMMUNE THERAPEUTICS PLC | Direttore/Membro del Consiglio | 01/11/2023 |
| The University of California, San Francisco | Corporate Officer/Principal | 01/07/1996 |
Precedenti posizioni note di Kristen Hege
| Società | Posizione | Fine |
|---|---|---|
| ARCUS BIOSCIENCES, INC. | Direttore/Membro del Consiglio | 20/11/2019 |
| CELGENE | Corporate Officer/Principal | 01/11/2019 |
Society For Immunotherapy of Cancer
 Society For Immunotherapy of Cancer Miscellaneous Commercial ServicesCommercial Services The Society for Immunotherapy of Cancer (SITC) is an organization that advances the science, development, and application of immunotherapy to improve cancer patient outcomes. The non-profit company is based in Milwaukee, WI. SITC conducts policy and advocacy efforts on behalf of its members and the field. The Journal for Immunotherapy of Cancer (JITC) is the official open access, peer-reviewed online journal of SITC, featuring original research articles, literature reviews, position papers, and discussions on all aspects of tumor immunology and cancer immunotherapy. SITC also created a conceptual framework for potential value in phase III studies evaluating immunotherapy combinations. | Direttore/Membro del Consiglio | 01/01/2019 |
International Society for Biological Therapy of Cancer
 International Society for Biological Therapy of Cancer Miscellaneous Commercial ServicesCommercial Services The International Society for Biological Therapy of Cancer operates as a professional society of influential scientists, academicians, researchers, clinicians, and government representatives. The non-profit company is based in Milwaukee, WI. | Direttore/Membro del Consiglio | 01/01/2019 |
California Life Sciences Association
 California Life Sciences Association Miscellaneous Commercial ServicesCommercial Services California Life Sciences Association (CLSA) is the largest and most influential life sciences advocacy and business leadership organization in California. The non-profit company is based in South San Francisco, CA, and has offices in other locations as well. The company works closely with industry, government, academia, and others to shape public policy, improve access to innovative technologies, and grow California's life sciences economy. CLSA serves biotechnology, pharmaceutical, medical device, and diagnostics companies, research universities and institutes, investors, and service providers throughout the state. Mike Guerra has been the CEO of the company since 2019. | Direttore/Membro del Consiglio | 01/01/2016 |
Formazione di Kristen Hege
| The University of California, San Francisco | Doctorate Degree |
| Dartmouth College | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 4 |
|---|---|
| MERSANA THERAPEUTICS, INC. | Health Technology |
| ARCUS BIOSCIENCES, INC. | Health Technology |
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| ADAPTIMMUNE THERAPEUTICS PLC | Health Technology |
| Aziende private | 11 |
|---|---|
Celgene Corp.
 Celgene Corp. BiotechnologyHealth Technology Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include Revlimid, Pomalyst, Imnovid, Otezla, Abraxane, and Vidaza. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ. | Health Technology |
Cell Genesys, Inc.
 Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | Health Technology |
Theraclone Sciences, Inc.
 Theraclone Sciences, Inc. Miscellaneous Commercial ServicesCommercial Services Theraclone Sciences, Inc. develops novel therapeutic antibodies for the treatment of cancer and infectious diseases. The firm leverages its proprietary antibody discovery technology, I-STARTM to identify rare fully human antibodies from immunologically relevant human subjects. The firm’s primary research focus is to discover novel targets and antibodies, and develop therapeutic monoclonal antibodies, by using its proprietary B-cell technology platform to mine the immune system of cancer patients. The company was founded by Johnny T. Stine in November 2004 and is headquartered in Seattle, WA. | Commercial Services |
Aragon Pharmaceuticals, Inc.
 Aragon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aragon Pharmaceuticals, Inc. develops biopharmaceutical products, It offers a pipeline of new anti-endocrine therapies targeting the biology of hormone resistant cancers. The company was founded by Charles L. Sawyers and Michael Jung on May 1, 2009 and is headquartered in San Diego, CA. | Health Technology |
Cellerant Therapeutics, Inc.
 Cellerant Therapeutics, Inc. Medical SpecialtiesHealth Technology Cellerant Therapeutics, Inc. develops stem cell-based cellular and antibody therapeutics for blood disorders and cancer. The firm focuses on curative therapies for seriously ill patients and is developing a cell-based medicine as a treatment for chemotherapy and radiation-induced neutropenia as well as for Acute Radiation Syndrome. The company was founded by Irving L. Weissman in 2003 and is headquartered in San Carlos, CA. | Health Technology |
California Biomedical Innovation Alliance
 California Biomedical Innovation Alliance BiotechnologyHealth Technology California Biomedical Innovation Alliance provides biomedical advocacy and community services. The private company is based in South San Francisco, CA and has subsidiaries in United States. The CEO of the company is Sara Radcliffe. | Health Technology |
| Baybio Institute | |
International Society for Biological Therapy of Cancer
International Society for Biological Therapy of Cancer Miscellaneous Commercial ServicesCommercial Services The International Society for Biological Therapy of Cancer operates as a professional society of influential scientists, academicians, researchers, clinicians, and government representatives. The non-profit company is based in Milwaukee, WI. | Commercial Services |
California Life Sciences Association
California Life Sciences Association Miscellaneous Commercial ServicesCommercial Services California Life Sciences Association (CLSA) is the largest and most influential life sciences advocacy and business leadership organization in California. The non-profit company is based in South San Francisco, CA, and has offices in other locations as well. The company works closely with industry, government, academia, and others to shape public policy, improve access to innovative technologies, and grow California's life sciences economy. CLSA serves biotechnology, pharmaceutical, medical device, and diagnostics companies, research universities and institutes, investors, and service providers throughout the state. Mike Guerra has been the CEO of the company since 2019. | Commercial Services |
Graphite Bio, Inc.
 Graphite Bio, Inc. BiotechnologyHealth Technology Graphite Bio, Inc. is a clinical-stage gene editing company. It engages in the business of developing therapies that harness targeted gene integration to treat or cure serious diseases. The company was founded by Matthew Porteus and Maria Grazia Roncarolo on June 1, 2017 and is headquartered in South San Francisco, CA. | Health Technology |
Society For Immunotherapy of Cancer
Society For Immunotherapy of Cancer Miscellaneous Commercial ServicesCommercial Services The Society for Immunotherapy of Cancer (SITC) is an organization that advances the science, development, and application of immunotherapy to improve cancer patient outcomes. The non-profit company is based in Milwaukee, WI. SITC conducts policy and advocacy efforts on behalf of its members and the field. The Journal for Immunotherapy of Cancer (JITC) is the official open access, peer-reviewed online journal of SITC, featuring original research articles, literature reviews, position papers, and discussions on all aspects of tumor immunology and cancer immunotherapy. SITC also created a conceptual framework for potential value in phase III studies evaluating immunotherapy combinations. | Commercial Services |
- Borsa valori
- Insiders
- Kristen Hege
